Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen

@article{Meriggiola2015EndocrineCO,
  title={Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen},
  author={Maria Cristina Meriggiola and Giulia Gava},
  journal={Clinical Endocrinology},
  year={2015},
  volume={83}
}
The treatment of transwomen relies on the combined administration of anti‐androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short… 

Andrology of male‐to‐female transsexuals: influence of cross‐sex hormone therapy on testicular function

There is a need for more individualized and better‐controlled cross‐sex hormone therapy and post‐treatment regimens, and evidence‐based guidelines for attending clinicians need to be established in order to deliver the most appropriate care.

Bone health in transgender people: a narrative review

To evaluate the risk of osteoporosis, it is mandatory to define the most appropriate reference group not only taking into consideration the medical aspects but also in respect of the selected gender identity of each person.

Variation of meningioma in response to cyproterone acetate in a trans woman

A conservative approach with interruption of cyproterone acetate may be a sufficient intervention, obviating the need for additional neurosurgical treatment of a trans woman diagnosed with a meningioma.

Contraception across transgender

Transgender men and women need to be counseled concerning contraceptive options and potential effects of treatment on reproductive function before initiating gender-affirming hormonal treatments (GAHTs), which may induce a varying degree of reversible loss of fertility.

Fertility preservation for transgender adolescents and young adults: a systematic review.

From a synthesis of the literature, it is concluded that there are many barriers preventing TAYAs from pursuing FP, including a lack of awareness of FP options, high costs, invasiveness of the available procedures and the potential psychological impact of the FP process.

Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness

To retrospectively compare the effectiveness and safety of 1‐year administration of transdermal oestradiol (TE) with cyproterone acetate (CPA) or leuprolide acetate (Leu) in transwomen.

Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review

This report highlights the importance to record all the cases of meningiomas in high dose CPA-users, in order to improve data, and may suggest use of alternative treatment for transwomen.

Scalp Hair Regrowth in Hormone-Treated Transgender Woman

The case of a transgender woman with scalp hair regrowth after ∼6 months on oral estradiol and spironolactone therapy achieving testosterone levels within normal female range is presented.

Disease screening and prevention for transgender and gender-diverse adults

How exogenous use of sex steroids provided as hormone therapy and gender-affirming procedures affect screening and prevention of sexually transmitted infections is focused on.

References

SHOWING 1-10 OF 80 REFERENCES

Long-term cross-sex hormone treatment is safe in transsexual subjects.

It is suggested that mortality is increased among transsexuals although due to causes unrelated to cross sex replacement therapy, which will benefit the care and treatment of these subjects.

Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.

The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people.

Venous thrombo‐embolism as a complication of cross‐sex hormone treatment of male‐to‐female transsexual subjects: a review

It seems advisable to stop hormone use at least 2 weeks before major surgery, to be resumed only after 3 weeks following full mobilisation, and other oral oestrogens should not be overdosed, and transdermal oestrogen is to be preferred.

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management.

Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.

Self-medication with estrogen is significantly more likely to result in a later request for mammoplasty than is treatment prescribed by licensed practitioners and CEE treatment is associated with a higher incidence of thromboembolism than treatment with other estrogen types.

Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective.

These guidelines are structured to provide evidence-based suggestions or, where evidence is lacking, expert recommendations on diagnostic procedures and hormonal treatment in adolescent and adult transsexuals, including long-term care and eligibility for surgery.

Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.

Current treatment modalities were effective and carried a low risk for side effects and adverse events at short-time follow-up, and side effects, adverse events, and desired clinical changes were examined.

Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study.

A positive effect of hormone therapy on transsexuals' QoL is suggested after accounting for confounding factors, which will be useful for healthcare providers of transgender persons but should be confirmed with larger samples using a prospective study design.

Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking.

Long‐term follow‐up of bone mineral density and bone metabolism in transsexuals treated with cross‐sex hormones

It is unknown whether long term cross‐sex hormone treatment affects the human skeleton, and bone mineral density and biochemical markers of bone turnover in male‐to‐female transsexuals treated with anti‐androgens and oestrogens and those treated with androgens are monitored.
...